首页> 外文期刊>Italian Journal of Medicine >Multidrug-resistant Gram-negative bacteria-resistant infections: epidemiology, clinical issues and therapeutic options
【24h】

Multidrug-resistant Gram-negative bacteria-resistant infections: epidemiology, clinical issues and therapeutic options

机译:多药耐药革兰氏阴性菌耐药感染:流行病学,临床问题和治疗选择

获取原文
           

摘要

In the last decade, we have witnessed a dramatic increase in the number of multidrug resistant Gram-negative (MDRGN) bacterial pathogens, both in Italy and worldwide, with Enterobacteriacae (mostly Klebsiella pneumoniae ), Pseudomonas aeruginosa and Acinetobacter baumannii being the major threats in clinical practice. Inadequate empirical antimicrobial therapy of severe infections caused by MDR Enterobacteriacae has been associated with an increased morbidity and mortality. However, a careful selection of patients who may receive empirical treatment covering MDR Enterobacteriacae is important to avoid the overuse of broad-spectrum antibiotics. The aim of this review is to describe the mechanism of resistance, epidemiology, risk factors, clinical issues, and therapeutic options for MDRGN pathogens.
机译:在过去十年中,我们目睹了意大利和世界范围内多重耐药的革兰氏阴性(MDRGN)细菌病原体的数量急剧增加,其中肠杆菌(主要为肺炎克雷伯菌),铜绿假单胞菌和鲍曼不动杆菌是该病的主要威胁临床实践。对由耐多药肠杆菌引起的严重感染的经验性抗菌药物治疗不足,已导致发病率和死亡率增加。但是,仔细选择可能接受MDR肠杆菌科治疗的患者对避免过度使用广谱抗生素很重要。这篇综述的目的是描述抗药性,流行病学,危险因素,临床问题以及对MDRGN病原体的治疗选择的机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号